idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Pharmacotherapy

Nintedanib

  • A receptor blocker for multiple kinases
  • Mediates the elaboration of fibrogenic growth factors:
    • Vascular endothelial growth factor receptors (VEGFR) 1-3
    • Fibroblast growth factor receptors (FGFR) 1-3
    • Platelet-derived growth factor receptors (PDGFR) 
  • Its efficacy in idiopathic pulmonary fibrosis were evaluated in INPULSIS-1 & -2, a randomized, double-blind, placebo controlled, 52-week duration, phase III trial, with the rate of decline of forced vital capacity (FVC) in a patient with idiopathic pulmonary fibrosis significantly reduced at the end of the study

Pirfenidone

  • A synthetic pyridone compound & an antibiotic agent that:
    • Inhibits the transforming growth factor beta (TGF-β)
    • Decreases the extracellular matrix
    • Blocks fibroblast proliferation in vitro 
  • Recommended for patients with mild-to-moderate disease
  • Slows the progression of lung impairment in patients with pulmonary fibrosis due to Hermansky-Pudlak syndrome
  • Based on the 2 Clinical studies Assessing Pirfenidone in idiopathic pulmonary fibrosis 004 & 006 (CAPACITY), Pirfenidone reduced both all-cause & IPF-related mortalities at 52 weeks
  • ASsessment of Pirfenidone to Confirm Efficacy aND safety of idiopathic pulmonary fibrosis (ASCEND) is a randomized, placebo-controlled, double-blind trial that was required by the US Food & Drug Administration (US FDA) to confirm its effectivity on disease progression showed a reduction in the decline of forced vital capacity at week 52 & a decrease by 43% to the risk of death
  • The safety of both trials (ASCEND & CAPACITY) were both demonstrated

Systemic Glucocorticoids

  • Recommended for confirmed idiopathic pulmonary fibrosis during acute exacerbations
  • The given dose is tapered based on the severity of the disease & patient's response to therapy
    • In patients who responds to therapy, the dose is slowly tapered (weeks-months)
    • Patients are then closely followed-up & monitored, to ensure that there is no recurrence of the disease

Other Treatments

  • Use of Ambrisentan, Warfarin, Imatinib, or combination Prednisone/Azathioprine/N-acetylcysteine for idiopathic pulmonary fibrosis is not strongly opposed by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, & the Latin American Thoracic Association
  • Treatment with Sildenafil, Bosentan, Macitentan, or N-acetylcysteine monotherapy for idiopathic pulmonary fibrosis is not recommended but may be considered in special conditions
    • Some studies cited improvement in shortness of breath, quality of life, arterial oxygen saturation with Sildenafil use
    • Two studies reported improvements in 6MWT distance while other studies have not found any significant difference in patients given N-acetylcysteine monotherapy
    • Further studies are needed to weigh the use of Sildenafil, Bosentan, Macitentan, & N-acetylcysteine monotherapy in idiopathic pulmonary fibrosis

Non-Pharmacological Therapy

Home Pulse Oximetry

  • It is noninvasive & is used to assess arterial oxygen saturation of hemoglobin (SpO2)
    • Light-absorbing variations from arterial blood flow pulsation are measured 
  • Used for monitoring & maintaining of the SpO2 level to >90%
    • If maintained, the development of a secondary pulmonary hypertension would be prevented

Supplemental Oxygen Therapy

  • Patients with acute exacerbation of idiopathic pulmonary fibrosis have a high oxygen requirement because they need to maintain a pulse oxygen saturation of >88%
  • In patients with acute exacerbation of idiopathic pulmonary fibrosis, hypoxemia is treated with supplemental oxygen
    • This may be sufficient to treat dyspnea but they must be monitored regularly as dyspnea due to idiopathic pulmonary fibrosis may be refractory 
  • Dyspnea upon exertion may be relieved by ambulatory or long-term oxygen therapy
  • Long-term oxygen therapy is recommended for idiopathic pulmonary fibrosis patients with clinically significant resting hypoxemia
  • Mechanical ventilation is not recommended for acute exacerbation of idiopathic pulmonary fibrosis

Pulmonary Rehabilitation

  • It improves symptoms, capacity to do exercises (eg walking distance) & quality of life, & reduces the severity of dyspnea of patients with idiopathic pulmonary fibrosis
  • The rehabilitation programs should be based on the severity of the disease

Clinical Trials

  • Patients with idiopathic pulmonary fibrosis are encouraged to join & participate in clinical trials of emerging therapies
    • The ideal candidate for a clinical trial is a patient with mild to moderate idiopathic pulmonary fibrosis 
  • Information about the trial will be provided for each patient & its assignment would depend on the patient’s assessment & condition
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
15 Jul 2018
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.